Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator’s product
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2875
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator’s product ; volume:12 ; number:1 ; day:30 ; month:5 ; year:2013 ; pages:1-8 ; date:12.2013
Malaria journal ; 12, Heft 1 (30.5.2013), 1-8, 12.2013
- Creator
-
Minzi, Omary MS
- Contributor
-
Marealle, Ignace A.
Shekalaghe, Seif
Juma, Omar
Ngaimisi, Eliford
Chemba, Mwajuma
Rutaihwa, Mastidia
Abdulla, Salim
Sasi, Philip
SpringerLink (Online service)
- DOI
-
10.1186/1475-2875-12-174
- URN
-
urn:nbn:de:1111-2016080639178
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Minzi, Omary MS
- Marealle, Ignace A.
- Shekalaghe, Seif
- Juma, Omar
- Ngaimisi, Eliford
- Chemba, Mwajuma
- Rutaihwa, Mastidia
- Abdulla, Salim
- Sasi, Philip
- SpringerLink (Online service)
Other Objects (12)
The clinical efficacy of artemether/lumefantrine (Coartem®)
Comparison of malaria treatment outcome of generic and innovator’s anti-malarial drugs containing artemether–lumefantrine combination in the management of uncomplicated malaria amongst Tanzanian children
Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
Investigations on the neurotoxic effects of the anti-malaria components artemether and artemether-lumefantrine in dogs
Development of a dissolution method for lumefantrine and artemether in immediate release fixed dose artemether/lumefantrine tablets
Modelling the optimal dosing schedule for artemether-lumefantrine chemoprophylaxis against malaria
The drug transporter ABCB1 c.3435C>T SNP influences artemether–lumefantrine treatment outcome
From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia
Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial
Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine
Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling
A dietary strategy for the management of artemether-lumefantrine-induced cardiovascular and renal toxicity
The clinical efficacy of artemether/lumefantrine (Coartem®)
Comparison of malaria treatment outcome of generic and innovator’s anti-malarial drugs containing artemether–lumefantrine combination in the management of uncomplicated malaria amongst Tanzanian children
Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
Investigations on the neurotoxic effects of the anti-malaria components artemether and artemether-lumefantrine in dogs
Development of a dissolution method for lumefantrine and artemether in immediate release fixed dose artemether/lumefantrine tablets
Modelling the optimal dosing schedule for artemether-lumefantrine chemoprophylaxis against malaria
The drug transporter ABCB1 c.3435C>T SNP influences artemether–lumefantrine treatment outcome
From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia
Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial
Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine
Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling
A dietary strategy for the management of artemether-lumefantrine-induced cardiovascular and renal toxicity
The clinical efficacy of artemether/lumefantrine (Coartem®)
Comparison of malaria treatment outcome of generic and innovator’s anti-malarial drugs containing artemether–lumefantrine combination in the management of uncomplicated malaria amongst Tanzanian children
Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients
Investigations on the neurotoxic effects of the anti-malaria components artemether and artemether-lumefantrine in dogs
Development of a dissolution method for lumefantrine and artemether in immediate release fixed dose artemether/lumefantrine tablets
Modelling the optimal dosing schedule for artemether-lumefantrine chemoprophylaxis against malaria
The drug transporter ABCB1 c.3435C>T SNP influences artemether–lumefantrine treatment outcome
From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia
Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial
Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine
Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling